The efficacy of drug-eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombus
Abstract Transarterial chemoembolization (TACE) combined with apatinib has been used for advanced hepatocellular carcinoma (HCC), and the efficacy is good. The study was conducted to compare the efficacy and safety of drug-eluting bead TACE plus apatinib (D-TACE-A) with conventional TACE plus apatin...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-04-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-09609-8 |
| _version_ | 1819210073207996416 |
|---|---|
| author | Weihua Zhang Linxia Wu Lei Chen Tao Sun Yanqiao Ren Bo Sun Licheng Zhu Ping Han Chuansheng Zheng |
| author_facet | Weihua Zhang Linxia Wu Lei Chen Tao Sun Yanqiao Ren Bo Sun Licheng Zhu Ping Han Chuansheng Zheng |
| author_sort | Weihua Zhang |
| collection | DOAJ |
| description | Abstract Transarterial chemoembolization (TACE) combined with apatinib has been used for advanced hepatocellular carcinoma (HCC), and the efficacy is good. The study was conducted to compare the efficacy and safety of drug-eluting bead TACE plus apatinib (D-TACE-A) with conventional TACE plus apatinib (C-TACE-A) in the treatment of HCC with portal vein tumor thrombus (PVTT). A total of 130 continuous patients who received D-TACE-A or C-TACE-A were included in the study from January 2017 to June 2020. Propensity score matching (PSM) was used to reduce potential selection bias. Before PSM, the median overall survival (mOS) (14 months) and median progression-free survival (mPFS) (7 months) in the C-TACE-A group were longer than the mOS (9 months; P = 0.001) and mPFS (4 months; P = 0.001) in the D-TACE-A group. After PSM, the mOS (14 months vs 9 months; P = 0.039) and mPFS (7 months vs 5 months; P = 0.009) in the C-TACE-A group were longer than those in the D-TACE-A group. In the multivariate regression analysis, C-TACE-A reduced the mortality rate and tumor progression rate compared with D-TACE-A. For the subgroup analysis, patients with VP1–2, without extrahepatic metastases, and with multiple TACE sessions who received C-TACE-A had a lower death risk and tumor progression risk than patients who received D-TACE-A. Before PSM, there was no statistically significant difference in any grade or grade III/IV adverse events (all P > 0.05). C-TACE-A could prolong mOS and mPFS in patients with PVTT, especially for patients with VP1–2 stage PVTT, no extrahepatic tumor metastases, and multiple TACE sessions. |
| first_indexed | 2024-12-23T06:05:22Z |
| format | Article |
| id | doaj.art-a44660a408f34cb48bec0af20d2f3a95 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-23T06:05:22Z |
| publishDate | 2022-04-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-a44660a408f34cb48bec0af20d2f3a952022-12-21T17:57:35ZengNature PortfolioScientific Reports2045-23222022-04-0112111110.1038/s41598-022-09609-8The efficacy of drug-eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombusWeihua Zhang0Linxia Wu1Lei Chen2Tao Sun3Yanqiao Ren4Bo Sun5Licheng Zhu6Ping Han7Chuansheng Zheng8Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAbstract Transarterial chemoembolization (TACE) combined with apatinib has been used for advanced hepatocellular carcinoma (HCC), and the efficacy is good. The study was conducted to compare the efficacy and safety of drug-eluting bead TACE plus apatinib (D-TACE-A) with conventional TACE plus apatinib (C-TACE-A) in the treatment of HCC with portal vein tumor thrombus (PVTT). A total of 130 continuous patients who received D-TACE-A or C-TACE-A were included in the study from January 2017 to June 2020. Propensity score matching (PSM) was used to reduce potential selection bias. Before PSM, the median overall survival (mOS) (14 months) and median progression-free survival (mPFS) (7 months) in the C-TACE-A group were longer than the mOS (9 months; P = 0.001) and mPFS (4 months; P = 0.001) in the D-TACE-A group. After PSM, the mOS (14 months vs 9 months; P = 0.039) and mPFS (7 months vs 5 months; P = 0.009) in the C-TACE-A group were longer than those in the D-TACE-A group. In the multivariate regression analysis, C-TACE-A reduced the mortality rate and tumor progression rate compared with D-TACE-A. For the subgroup analysis, patients with VP1–2, without extrahepatic metastases, and with multiple TACE sessions who received C-TACE-A had a lower death risk and tumor progression risk than patients who received D-TACE-A. Before PSM, there was no statistically significant difference in any grade or grade III/IV adverse events (all P > 0.05). C-TACE-A could prolong mOS and mPFS in patients with PVTT, especially for patients with VP1–2 stage PVTT, no extrahepatic tumor metastases, and multiple TACE sessions.https://doi.org/10.1038/s41598-022-09609-8 |
| spellingShingle | Weihua Zhang Linxia Wu Lei Chen Tao Sun Yanqiao Ren Bo Sun Licheng Zhu Ping Han Chuansheng Zheng The efficacy of drug-eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombus Scientific Reports |
| title | The efficacy of drug-eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombus |
| title_full | The efficacy of drug-eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombus |
| title_fullStr | The efficacy of drug-eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombus |
| title_full_unstemmed | The efficacy of drug-eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombus |
| title_short | The efficacy of drug-eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombus |
| title_sort | efficacy of drug eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombus |
| url | https://doi.org/10.1038/s41598-022-09609-8 |
| work_keys_str_mv | AT weihuazhang theefficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT linxiawu theefficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT leichen theefficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT taosun theefficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT yanqiaoren theefficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT bosun theefficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT lichengzhu theefficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT pinghan theefficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT chuanshengzheng theefficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT weihuazhang efficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT linxiawu efficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT leichen efficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT taosun efficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT yanqiaoren efficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT bosun efficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT lichengzhu efficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT pinghan efficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus AT chuanshengzheng efficacyofdrugelutingbeadorconventionaltransarterialchemoembolizationplusapatinibforhepatocellularcarcinomawithportalveintumorthrombus |